Loading organizations...
§ Private Profile · 3525 Del Mar Heights Rd Ste 609, San Diego, California, 92130, United States
Recros Medica is a technology company.
Recros Medica develops medical aesthetic technology addressing skin laxity and focal contouring. Its Nuvellus™ platform uses proprietary Rotational Fractional Resection (RFR) technology. This minimally invasive system offers a unique, single-treatment solution for concerns like submental contouring, precisely remodeling tissue to enhance skin appearance via advanced mechanical intervention.
Founded in 2014 by Dr. Edward Knowlton, David Hale, and Cathy McCarthy, Recros Medica leverages deep aesthetic expertise. Dr. Knowlton, a board-certified plastic surgeon, previously invented Thermage. This background fueled the insight to develop new, less invasive medical devices for skin tightening and contouring, advancing aesthetic treatment.
The Nuvellus™ platform targets dermatologists, plastic surgeons, and other aesthetic professionals. Recros Medica’s vision is to lead medical aesthetics by innovating devices that deliver lasting improvements in skin quality and contour. The company empowers practitioners with sophisticated, patient-friendly technologies, addressing evolving demands for non-surgical aesthetic enhancements.
Recros Medica has raised $32.0M across 3 funding rounds.
Recros Medica has raised $32.0M in total across 3 funding rounds.
Recros Medica is a medical device company specializing in developing innovative technologies to treat skin laxity and focal aesthetic contour deformities. Their core product platform, called Rotational Fractional Resection, targets multiple clinical applications in the medical aesthetics field, aiming to improve patients' appearance by addressing common skin and contour issues. The company serves medical professionals and aesthetic practitioners who require advanced, effective solutions for non-invasive or minimally invasive cosmetic treatments. Recros Medica is positioned in the growing aesthetic medical device market, leveraging technology to meet increasing demand for skin rejuvenation and contour correction[1][3][4].
Recros Medica was founded as a privately held company focused on research, development, and manufacturing of aesthetic medical products. While specific founding year and founders' details are not publicly detailed, the company has evolved around its proprietary technology platform, Rotational Fractional Resection, which represents a novel approach in the aesthetic device space. Early traction likely came from clinical validation and adoption by aesthetic practitioners seeking improved treatment modalities for skin laxity and contour deformities[3][4].
Recros Medica operates within the expanding medical aesthetics market, which is driven by increasing consumer demand for minimally invasive cosmetic procedures and technological advancements in skin treatment. The timing is favorable due to rising awareness of aesthetic health, aging populations, and technological progress in medical devices. By introducing a novel technology platform, Recros Medica contributes to advancing treatment options, potentially influencing standards of care and encouraging further innovation in the aesthetic device ecosystem[1][3].
Looking ahead, Recros Medica is poised to capitalize on growing market trends favoring non-invasive aesthetic treatments. Continued clinical validation, regulatory approvals, and adoption by practitioners will be critical to their growth momentum. Emerging trends such as personalized aesthetic treatments and integration of digital technologies could shape their product evolution. As the company expands its clinical applications and market reach, it may become a significant player influencing the future landscape of medical aesthetics, tying back to its mission of enhancing appearance through innovative technology[1][3][4].
Recros Medica has raised $32.0M in total across 3 funding rounds.
Recros Medica's investors include Shanghai Haohai Biological Technology, Christoph Westphal, Longwood Fund, Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, Polaris Partners.
Recros Medica has raised $32.0M across 3 funding rounds. Most recently, it raised $14.0M Series A in November 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 19, 2019 | $14M Series A | Shanghai Haohai Biological Technology | — | Announced |
| Jan 4, 2018 | $9M Venture Round | Christoph Westphal | — | Announced |
| Jan 1, 2018 | $9M Series U | Longwood Fund | Abingworth, Advanced Technology Ventures, Lightspeed Venture Partners, Polaris Partners | Announced |